AI drug development company Vasgene Bio announced on the 4th that it presented three research results at the American Society of Human Genetics (ASHG), including Alzheimer's research using its proprietary biomarker discovery technology TLBM (Time-based Biomarker Mining) and gene-based gout drug repurposing research using the AI drug development platform DEEPCT (DEEP learning based Clinical Trial).
The American Society of Human Genetics (ASHG) is the world's largest academic conference in the field of genetics, attended annually by more than 6,000 genome research institutions and over 200 corporate representatives, where research results and related advanced technologies are presented and communicated. Due to COVID-19, this year marked the first in-person event in three years.
At this conference, the three studies presented by Vasgene Bio as poster presenters were genome research based on proprietary data and technology: ▲ "Exploration and validation of new genetic loci related to Alzheimer's disease" conducted through meta-analysis linked with time biomarkers that calculate disease onset risk time, ▲ "Gene-based simulation study on the risk of cardiovascular disease occurrence from gout drugs" using the AI drug development platform DEEPCT, and ▲ "Gene-based analysis of the correlation between BMI and uric acid levels" based on an exclusive cohort dataset of approximately 160,000 genomes.
Through this research, Vasgene Bio established academic evidence for its independently developed time biomarker discovery technology (TLBM) and AI drug development platform DEEPCT, demonstrating that its exclusively secured data can be utilized not only for disease cohort studies but also for discovering new biomarkers for various cancer types and drug repurposing.
The research results are scheduled to be published in domestic and international journals. Vasgene Bio is advancing into the drug development field with research and development that can contribute to disease prevention, diagnosis, and treatment progress, strengthening mutual cooperation with domestic and international pharmaceutical companies for joint drug development and technology commercialization, and expanding its global business.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
